US2014044737A1PendingUtilityA1

Rbp4 in insulin sensitivity/resistance, diabetes, and obesity

65
Assignee: BETH ISRAEL HOSPITALPriority: Dec 11, 2003Filed: Oct 24, 2013Published: Feb 13, 2014
Est. expiryDec 11, 2023(expired)· nominal 20-yr term from priority
Inventors:Barbara B. KahnQin YangTim GrahamOdile Peroni
C12Q 2600/136G01N 2500/00G01N 2800/042A61K 31/167G01N 33/5088A61P 3/10A61P 3/08C12Q 2600/106C12Q 2600/158C07K 14/705A61K 48/00C12Q 1/6883A61K 49/0008G01N 33/6893
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of reducing insulin resistance in a mammal, comprising administering to a mammal a compound that reduces RBP4 activity. 
     
     
         2 . The method of  claim 1  wherein the activity of RBP4 is expression of RBP4 mRNA. 
     
     
         3 . The method of  claim 1  wherein the activity of RBP4 is binding of RBP4 to cells. 
     
     
         4 . The method of  claim 3  wherein the cells are selected from the group consisting of: adipose, liver or muscle. 
     
     
         5 . The method of  claim 1  wherein the RBP4 activity is binding of RBP4 to transthyretin. 
     
     
         6 . The method of  claim 5  wherein the binding to transthyretin is inhibited or reduced.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.